For Immediate Release:

November 12, 2019

**The CCMR and the Cornell CAT collaborate to help New York State Life Sciences companies advance technologies towards commercialization!**

**Ithaca, NY -** The Cornell Center for Materials Research Industrial Partnerships Program is designed to help New York State’s businesses access world-class capabilities; solve technical challenges; and develop and improve their products, with the ultimate goals of revenue growth and job creation.

The Cornell Center for Advanced Technology (CAT) supports collaborative projects with New York State Life Sciences industry partners enabling them to advance an early stage technology, moving it closer to commercialization. The CCMR sponsors selected awarded CAT projects having materials-related needs, including the development or use of materials in their biotechnology and medical applications or prototypes.

Two projects were selected by CCMR:

* Prof. Lawrence Bonassar, Biomedical Engineering, is working with 3DBio Therapeutics, New York NY, a startup developing clinical grade collagen gels for multiple medical applications. The team focuses on the development of injectable collagen-based materials for the sealing of herniated discs. The project’s goal is to benchmark materials made by 3DBio for their mechanical properties, integration with disc tissue, and restoration of performance to sheep motion segments in comparison to our current formulation that has proven effective in vivo in rats and sheep.
* Prof. Laura Goodman, Veterinary Medicine, is partnering with bioWALL LLC, Slingerlands NY, to develop a knowledge-base and commercial platform that aims to promote best practices in industrial hygiene and biosecurity in the veterinary environment. This project’s goal is to improve the operation of clinical and diagnostic veterinary practices by providing: (1) a better understanding of animal disease issues in the working environment; (2) a relative reduction in viral and bacterial contamination rates; (3) the potential to stop a contamination event before it starts.

The CCMR sponsorship amounts to $5,000 per project. The program is also supported by Empire State Development’s Division of Science, Technology and Innovation (NYSTAR).

**About the Cornell Center for Materials Research (CCMR)**

The Cornell Center for Materials Research is a National Science Foundation and New York State funded interdisciplinary research center at Cornell University whose mission is to advance, explore, and exploit the forefront of the science and engineering of advanced materials. The CCMR pursues this objective through fundamental, experimental and theoretical studies. Three other complementary functions complete the CCMR’s mission: educational outreach to teachers and students; industrial outreach and knowledge transfer; and the operation of shared instrumentation in support of materials research both on and off campus. [www.ccmr.cornell.edu/industry](http://www.ccmr.cornell.edu/industry)

**About the Cornell Center for Advanced Technology**

The Center for Advanced Technology (CAT) program supports entrepreneurial development for life scientists and biotechnology industries in New York State. It is funded and designated by [NYSTAR](http://esd.ny.gov/nystar/). The CAT provides opportunity and infrastructure linking academic research with commercial interests to facilitate commercialization of life sciences inventions that grow the New York State economy.

http://www.biotech.cornell.edu/cat

**About Empire State Development’s Division of Science, Technology and Innovation**

Empire State Development’s Division of Science, Technology and Innovation (NYSTAR) supports collaborative industry/academic partnerships to foster integrated approaches for developing and commercializing innovative technologies. NYSTAR serves as a resource for small and startup technology companies. For more information, please visit [www.esd.ny.gov/nystar/](http://www.esd.ny.gov/nystar/).

**About 3DBio Therapeutics**

3DBio Therapeutics is a biologics and bioprinting company with a focus on regenerative medicine that precision manufactures living tissues to allow replacement of each individual patient’s parts with tissues designed and created specifically for them. 3DBio has developed unique capabilities toward the creation of living tissue implants for therapeutic applications. The technology platforms include a full suite of features to meet the FDA’s requirements for therapeutic manufacturing, including novel and proprietary: 3D-bioprinter (GMPrint™), bio-ink (ColVivo™), and cell processes. In pre-clinical studies the platform has demonstrated the ability to generate functioning living tissues.

<https://3dbiocorp.com/>

**About bioWALL**

BioWALL delivers custom solutions to complex contamination issues faced by the agriculture and food industries. The company’s DiKlor® chlorine dioxide products are used on a daily basis to effectively mitigate microbiological threats to food production and processing. Following the anthrax attacks of 2001, DiKlor® technology was used to decontaminate all buildings impacted by anthrax spores. Since that time, bioWALL has adapted the same sterilization process used in bioterrorism response scenarios to solve complex biosecurity problems in farm and food production settings, Collectively, bioWALL’s service offerings in drinking water disinfection, facility biosecurity, and wide-are biological remediation contribute to a cleaner environment and create safer products for consumers.

<https://www.biowall.com/>

Contact:

Dr. Michèle van de Walle, MBA,

Industrial Partnerships Director,

T. 607 255 8809

industry@ccmr.cornell.edu